[
 {
  "trial": "T100",
  "source": "fulltext",
  "arms": {
   "Esketamine group (PE)": {
    "randomized": "66",
    "analysed": "58"
   },
   "Control group (C)": {
    "randomized": "66",
    "analysed": "58"
   }
  },
  "depression": [
   {
    "measure": "HADS depression score",
    "day": 1,
    "form": "difference",
    "location": "Discussion, second paragraph",
    "estimate": "1.5",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": null,
    "comparison": "Control group (C) minus Esketamine group (PE): 'HADS-D scores were 1.5 points lower in group PE'",
    "p": "< 0.05",
    "values": {
     "Esketamine group (PE)": {
      "n": "58"
     },
     "Control group (C)": {
      "n": "58"
     }
    },
    "direction": "lower in Esketamine group (PE) than in Control group (C)"
   },
   {
    "measure": "HADS depression score",
    "day": 3,
    "form": "difference",
    "location": "Discussion, second paragraph",
    "estimate": "1.5",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": null,
    "comparison": "Control group (C) minus Esketamine group (PE): 'HADS-D scores were 1.5 points lower in group PE'",
    "p": "< 0.05",
    "values": {
     "Esketamine group (PE)": {
      "n": "58"
     },
     "Control group (C)": {
      "n": "58"
     }
    },
    "direction": "lower in Esketamine group (PE) than in Control group (C)"
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Results, text ('no patients in either group developed headache, blurred vision, delirium, or block-related complications')",
    "values": {
     "Esketamine group (PE)": {
      "visual": "0"
     },
     "Control group (C)": {
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-09",
   "end": "2024-02",
   "location": "Methods (patients scheduled between September 2023 and February 2024 were included); the Results give no dates"
  },
  "registration": {
   "number": "ChiCTR2300075055",
   "date": "2023-08-23"
  },
  "note": "Tables 1-7 are not reproduced in the source (web 'Download CSV / Display Table' placeholders) and Figures 2-3 print no values, so no arm-level HADS-D, VAS or adverse-event counts are available. Results: HADS-D lower in group PE on postoperative days 1 and 3 (p < 0.05), no difference preoperatively or on day 7 (p > 0.05). The only depression number is the Discussion's 'Compared with group C, HADS-D scores were 1.5 points lower in group PE', given once for days 1 and 3 together; it is entered at both days as printed (1.5, control minus esketamine), but it is not said whether it applies to each day or is one figure for both, nor whether it is a mean or median difference (HADS analysed by repeated-measures ANOVA), so scale is null; no CI or exact p. Arm n = 58 per group from the notes to Figures 2 and 3 (116 completed with complete data). 132 randomized (66 per group), 16 dropped out. Group C is the 'placebo group'. Esketamine 0.5 mg/kg at induction plus 1 mg/kg in a 48 h PCIA. VAS (Table 5) and RASS: no values. Adverse events: only the zero for blurred vision is printed in words ('no patients in either group developed headache, blurred vision, delirium...'), recorded as visual 0; Table 7's postoperative agitation, hallucination and dizziness counts are not in the source, and delirium (none) is a separate item from postoperative agitation, so agitation is not entered. Enrollment from the Methods; the Results give no dates. Registration date printed 'August 23, 2023'. No blinding check.",
  "reason": "The coders differed only on the arm n's of the two HADS-D difference entries (A: 58 each; B: null). The codebook asks for the arm n's with a difference, and the note to Figure 3 (HADS-D at each time) prints 'Group C, placebo group (n = 58); group PE, esketamine group (n = 58)', so A's 58 per arm is kept. Started from A; added B's direction field beside A's comparison so the sign of 1.5 is explicit."
 },
 {
  "trial": "T120",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "168",
    "analysed": "164"
   },
   "Control group": {
    "randomized": "168",
    "analysed": "158"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "Esketamine group": {
      "median": "6",
      "q1": "4",
      "q3": "7",
      "n": "164"
     },
     "Control group": {
      "median": "5",
      "q1": "3",
      "q3": "8",
      "n": "158"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS ≥ 10 (PPD)",
    "values": {
     "Esketamine group": {
      "events": "8",
      "n": "164"
     },
     "Control group": {
      "events": "24",
      "n": "158"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "median_iqr",
    "location": "Table 2 (n from the PPD row's denominators at the same time)",
    "values": {
     "Esketamine group": {
      "median": "4",
      "q1": "2",
      "q3": "6",
      "n": "164"
     },
     "Control group": {
      "median": "5",
      "q1": "2",
      "q3": "8",
      "n": "158"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 30,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS ≥ 10 (PPD)",
    "values": {
     "Esketamine group": {
      "events": "13",
      "n": "158"
     },
     "Control group": {
      "events": "16",
      "n": "149"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 30,
    "form": "median_iqr",
    "location": "Table 2 (n from the PPD row's denominators at the same time)",
    "values": {
     "Esketamine group": {
      "median": "4",
      "q1": "2",
      "q3": "7",
      "n": "158"
     },
     "Control group": {
      "median": null,
      "q1": "2",
      "q3": "7",
      "n": "149"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 60,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS ≥ 10 (PPD)",
    "values": {
     "Esketamine group": {
      "events": "8",
      "n": "149"
     },
     "Control group": {
      "events": "13",
      "n": "145"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 60,
    "form": "median_iqr",
    "location": "Table 2 (n from the PPD row's denominators at the same time)",
    "values": {
     "Esketamine group": {
      "median": "4",
      "q1": "2",
      "q3": "7",
      "n": "149"
     },
     "Control group": {
      "median": "4",
      "q1": "2",
      "q3": "7",
      "n": "145"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 90,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS ≥ 10 (PPD)",
    "values": {
     "Esketamine group": {
      "events": "7",
      "n": "146"
     },
     "Control group": {
      "events": "10",
      "n": "143"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 90,
    "form": "median_iqr",
    "location": "Table 2 (n from the PPD row's denominators at the same time)",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "5",
      "n": "146"
     },
     "Control group": {
      "median": "4",
      "q1": "2",
      "q3": "7",
      "n": "143"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (24 h; Fig. 3a)",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "1",
      "q3": "4",
      "n": null
     },
     "Control group": {
      "median": "2",
      "q1": "1",
      "q3": "5",
      "n": null
     }
    }
   },
   {
    "measure": "effective PCIA presses",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (cumulative over the 24 h PCIA; Fig. 3b)",
    "values": {
     "Esketamine group": {
      "median": "6",
      "q1": "3",
      "q3": "10",
      "n": null
     },
     "Control group": {
      "median": "7",
      "q1": "3.5",
      "q3": "11",
      "n": null
     }
    }
   },
   {
    "measure": "sufentanil consumption",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (cumulative 24 h, μg, medians only; Fig. 3c)",
    "values": {
     "Esketamine group": {
      "median": "60",
      "q1": null,
      "q3": null,
      "n": null
     },
     "Control group": {
      "median": "62",
      "q1": null,
      "q3": null,
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "time": "within 1 h after drug administration (during caesarean section)",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "dizziness": "18",
      "hallucination": "17",
      "visual": "3",
      "dissociation": "9"
     },
     "Control group": {
      "dizziness": "0",
      "hallucination": "0",
      "visual": "0",
      "dissociation": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "24 h postpartum",
    "location": "Table 3; hallucination and dissociation from the Results text",
    "values": {
     "Esketamine group": {
      "dizziness": "21",
      "visual": "1",
      "hallucination": "0",
      "dissociation": "0"
     },
     "Control group": {
      "dizziness": "9",
      "visual": "0",
      "hallucination": "0",
      "dissociation": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-05-01",
   "end": "2024-03-31",
   "location": "Methods (trial conducted from 1 May 2021 to 31 March 2024, which includes the 3-month follow-up); the Results give no dates"
  },
  "registration": {
   "number": "NCT04860661",
   "date": "2021-04-20"
  },
  "note": "Esketamine 0.25 mg/kg 15 min after cord clamping plus 80 mg in the 24 h PCIA; control saline. 336 randomized, 168 per group; modified ITT 164 (esketamine: 1 converted to general anaesthesia, 3 lost) and 158 (control: 4 converted, 6 lost). Days: 7 days, 1, 2 and 3 months = 7, 30, 60, 90; baseline EPDS taken the day before surgery (Table 1). PPD = EPDS score of at least 10 (Table 2, n/total per time). Table 2's EPDS-score rows print no n of their own; their n is the denominator printed in the PPD row at the same time (the number screened then, under the 'n/total' column heading). The control median at 1 month is missing in print (the cell reads '[2 to 7]'), so it is null; Table 2's Hodges-Lehmann median difference there is 0 (−1 to 0), not entered because arm values are given. Also not entered: total PPD within 3 months as percentages only (11.59% vs 20.89%; adjusted RR 0.57, 95% CI 0.35 to 0.94). Pain: the 24 h NRS is used for day 1 (the 18 h value, 2 [1 to 4] vs 2 [1 to 4], is not recorded since the 24 h value is printed); PCIA presses are over the 24 h PCIA; sufentanil is printed as medians only (60 vs 62 μg, cumulative 24 h per Fig. 3c). Adverse events, Table 3: events within 1 h after drug administration occurred during the caesarean ('vanished before the end of surgery'), so intraoperative; nystagmus (intraoperative) and diplopia (24 h) recorded as visual. Hallucinations were euphoric 12, unpleasant 3, neutral 2 (unpleasant ones not counted as nightmares). Postoperative hallucination and dissociation zeros come from 'No patients experienced hallucination or dissociation after surgery.' Dizziness at 24 h by grade: I 19 vs 9, II 1 vs 0, III 1 vs 0. Nausea or vomiting is not a codebook category. Trial conducted 1 May 2021 to 31 March 2024 (Methods; includes follow-up); the Results give no dates. Registration date printed '20 April 2021'. No blinding check reported.",
  "reason": "The coders differed only on the n of Table 2's EPDS median rows at 7, 30, 60 and 90 days (A: 164/158, 158/149, 149/145, 146/143; B: null). The codebook's n is the number assessed at that time, if given; Table 2's columns are headed 'n/total' and its PPD rows print the number screened at each time, which is the same EPDS assessment the median rows summarise, so the source does give it. Kept A's n's and named their source in each row's location."
 },
 {
  "trial": "T014",
  "source": "abstract",
  "arms": {
   "Group K": {
    "randomized": null,
    "analysed": null
   },
   "Group C": {
    "randomized": null,
    "analysed": null
   }
  },
  "depression": [],
  "pain": [
   {
    "measure": "VAS pain in PACU, at 4 h, 24 h and days 2-5",
    "day": 1,
    "form": "mean_sd",
    "location": "abstract",
    "values": {
     "Group K": {
      "mean": "2.4",
      "sd": "0.5",
      "n": null
     },
     "Group C": {
      "mean": "2.6",
      "sd": "0.5",
      "n": null
     }
    }
   },
   {
    "measure": "VAS pain in PACU, at 4 h, 24 h and days 2-5",
    "day": 2,
    "form": "mean_sd",
    "location": "abstract",
    "values": {
     "Group K": {
      "mean": "2.0",
      "sd": "0.4",
      "n": null
     },
     "Group C": {
      "mean": "2.3",
      "sd": "0.5",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2015-06",
   "end": "2016-05"
  },
  "registration": null,
  "note": "Abstract only. 66 randomized in total; per-arm numbers not given (by 6 months 2 lost in group C, 1 in group K). HADS (preoperative, day 5, 3 and 6 months) reported only by significance statements, so no depression entries. The abstract lists VAS in the order PACU, 4 h, 24 h, 2 d, 3 d, 4 d, 5 d: group K (2.5±0.8), (2.4±0.5), (2.4±0.5), (2.0±0.4), (1.5±0.5), (1.0±0.4), 1(1); group C (2.9±1.0), (2.9±0.6), (2.6±0.5), (2.3±0.5), (1.8±0.6), (1.5±0.5), 1(0); day 1 is the 24 h value and day 2 the '2 d' value. '±' is not defined and is read as mean ± SD; no n is given for VAS. Analgesic consumption only as 'lower (all P<0.05)'. PMPS incidence at 3 and 6 months (25% and 22% vs 52% and 45%) is outside the day 1-2 pain window. No adverse events reported. Enrollment from the abstract's Methods ('From June 2015 to May 2016').",
  "reason": "The coders agreed on every value; they differed only in that A wrote 'n': null in the day 1 and day 2 VAS entries and B left the key out. The abstract gives no n for VAS (only 66 randomized in total), so n is null; kept A's explicit null, which matches the codebook's mean_sd fields. Checked the 24 h and 2 d values against the abstract's seven-value sequence."
 },
 {
  "trial": "T029",
  "source": "fulltext",
  "arms": {
   "S-ketamine group": {
    "randomized": "61",
    "analysed": "60"
   },
   "Placebo group": {
    "randomized": "63",
    "analysed": "60"
   }
  },
  "depression": [
   {
    "measure": "HAMD-17",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (same values in Table 1, n = 60 per group)",
    "values": {
     "S-ketamine group": {
      "mean": "19.0",
      "sd": "3.59",
      "n": "60"
     },
     "Placebo group": {
      "mean": "19.5",
      "sd": "3.73",
      "n": "60"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "10.7",
      "sd": "4.80",
      "n": null
     },
     "Placebo group": {
      "mean": "15.5",
      "sd": "5.04",
      "n": null
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 7,
    "form": "change_mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "−8.8",
      "sd": "3.27",
      "n": null
     },
     "Placebo group": {
      "mean": "−3.5",
      "sd": "2.17",
      "n": null
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (same values in Table 1, n = 60 per group)",
    "values": {
     "S-ketamine group": {
      "mean": "15.6",
      "sd": "2.65",
      "n": "60"
     },
     "Placebo group": {
      "mean": "15.2",
      "sd": "2.45",
      "n": "60"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "8.9",
      "sd": "3.45",
      "n": null
     },
     "Placebo group": {
      "mean": "13.0",
      "sd": "3.44",
      "n": null
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 7,
    "form": "change_mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "−6.7",
      "sd": "2.53",
      "n": null
     },
     "Placebo group": {
      "mean": "−2.2",
      "sd": "1.49",
      "n": null
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "opioid use during hospital stay (morphine equivalents)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 ('Postoperative opioid used, mg'); Results text gives the same values as consumption within 2 days after surgery",
    "values": {
     "S-ketamine group": {
      "mean": "16.4",
      "sd": "5.9",
      "n": "60"
     },
     "Placebo group": {
      "mean": "23.9",
      "sd": "8.4",
      "n": "60"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 3",
    "values": {
     "S-ketamine group": {
      "dizziness": "5"
     },
     "Placebo group": {
      "dizziness": "3"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-09-01",
   "end": "2022-03-01"
  },
  "registration": {
   "number": "NCT05506787",
   "date": null
  },
  "note": "Randomized 61 (S-ketamine) and 63 (placebo); 1 and 3 lost to follow-up; 60 per arm analysed. Tables list Placebo before S-Ketamine. HAMD-17 and PHQ-9 on days 1, 3 and 30 and NRS on days 1 and 2 are only in Figure 2, with no printed values, so only baseline and day 7 (Table 2) are entered. Table 2 gives no n; the baseline n of 60 is Table 1's header, where the same baseline values are printed with '±' (Table 1's footnote says number (%) and median (IQR); Table 2 labels them Mean (SD)). Change values keep the source's minus sign (U+2212) exactly as printed. The printed HAMD-17 changes (−3.5, −8.8) are not the day-7 minus baseline means (−4.0, −8.3), though their difference matches the printed treatment difference; recorded as printed. Table 2 also gives the day-7 treatment differences, Mean (SE) and 95% CI: HAMD-17 −5.3 (0.50), −6.3 to −4.3; PHQ-9 −4.5 (0.38), −5.2 to −3.7; not entered since arm values are given. Opioid: Methods describe use throughout the hospital stay (morphine equivalents), but the Results text gives the Table 3 values (16.4 [SD 5.9] vs 23.9 [SD 8.4]) as consumption within 2 days after surgery, so day 2 (cumulative). Adverse events from Table 3 (timing not stated; read as postoperative): 'Dizzy' 5 (8.3%) vs 3 (5%) as dizziness; 'Dysphoria' 4 (6.7) vs 1 (1.7%), which the text calls irritability, not coded to a category; nausea 3 (5%) vs 6 (10%) not a codebook category. Enrollment from the Results ('From 1 September 2020 to 1 March 2022, 151 patients ... were screened'). No registration date given. No blinding check.",
  "reason": "The coders differed on the minus sign of the day-7 change means (A: ASCII '-8.8', '-3.5', '-6.7', '-2.2'; B: '−8.8' etc.) and on whether the day-7 rows carry an n key. Table 2 prints these values with U+2212 minus signs, so B's strings are kept exactly as printed. Table 2 gives no n for day 7, so n is null; written as an explicit null rather than left out. Otherwise the coders agreed; added A's Table 3 location for the adverse events."
 },
 {
  "trial": "T035",
  "source": "library",
  "arms": {
   "S-ketamine group": {
    "randomized": "40",
    "analysed": "39"
   },
   "Saline group": {
    "randomized": "40",
    "analysed": "38"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "S-ketamine group": {
      "median": "5",
      "q1": "4",
      "q3": "7",
      "n": "39"
     },
     "Saline group": {
      "median": "6",
      "q1": "4",
      "q3": "7.8",
      "n": "38"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4",
    "values": {
     "S-ketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "6.0",
      "n": "39"
     },
     "Saline group": {
      "median": "6.0",
      "q1": "5.0",
      "q3": "8.0",
      "n": "38"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "count",
    "location": "Table 4",
    "definition": "HADS-D score >7",
    "values": {
     "S-ketamine group": {
      "events": "6",
      "n": "39"
     },
     "Saline group": {
      "events": "5",
      "n": "38"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes text",
    "values": {
     "S-ketamine group": {
      "mean": "2.5",
      "sd": "0.51",
      "n": null
     },
     "Saline group": {
      "mean": "2.8",
      "sd": "0.66",
      "n": null
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes text",
    "values": {
     "S-ketamine group": {
      "mean": "2.1",
      "sd": "0.61",
      "n": null
     },
     "Saline group": {
      "mean": "2.6",
      "sd": "0.76",
      "n": null
     }
    }
   },
   {
    "measure": "NRS when coughing",
    "day": 1,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes text",
    "values": {
     "S-ketamine group": {
      "mean": "3.6",
      "sd": "0.59",
      "n": null
     },
     "Saline group": {
      "mean": "4.3",
      "sd": "0.64",
      "n": null
     }
    }
   },
   {
    "measure": "NRS when coughing",
    "day": 2,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes text",
    "values": {
     "S-ketamine group": {
      "mean": "3.3",
      "sd": "0.57",
      "n": null
     },
     "Saline group": {
      "mean": "3.7",
      "sd": "0.69",
      "n": null
     }
    }
   },
   {
    "measure": "rescue analgesia requirement (IM bucinnazine)",
    "day": 2,
    "form": "count",
    "location": "Table 4",
    "definition": "patients given rescue analgesia within the 48 h study period",
    "values": {
     "S-ketamine group": {
      "events": "9",
      "n": "39"
     },
     "Saline group": {
      "events": "17",
      "n": "38"
     }
    }
   },
   {
    "measure": "rescue analgesia requirement (IM bucinnazine)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4",
    "values": {
     "S-ketamine group": {
      "median": "0.0",
      "q1": "0.0",
      "q3": "75.0",
      "n": "39"
     },
     "Saline group": {
      "median": "0.0",
      "q1": "0.0",
      "q3": "100.0",
      "n": "38"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "overall",
    "location": "Results, Secondary Outcomes text; Discussion",
    "values": {
     "S-ketamine group": {
      "visual": "1",
      "hallucination": "0",
      "dissociation": "0",
      "dizziness": "0",
      "nightmare": "0"
     },
     "Saline group": {
      "visual": "0",
      "hallucination": "0",
      "dissociation": "0",
      "dizziness": "0",
      "nightmare": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-05",
   "end": "2021-12"
  },
  "registration": {
   "number": "ChiCTR2100046552",
   "date": null
  },
  "note": "Library copy of the PDF ('§' is the extraction's rendering of '±'). Randomized 40 per arm from Statistical Analysis ('the authors enrolled 40 patients per group'; 80 enrolled, allocated 1:1); three were excluded after allocation, arms not stated; analysed 39 and 38 from the table headers. HADS-D at 48 h from Table 4; the text prints the same values without decimals (4 [3-6] v 6 [5-8]), Table 4's taken. Depression count: HADS-D score >7 (Table 4 footnote). NRS at 24 and 48 h from the Results text, which says 'mean NRS scores' and lists the S-ketamine value first (the values agree with 'lower in the S-ketamine group'); Figure 2 plots them with 95% CI error bars and prints no n, so n is null. The abstract gives p = 0.006 at 48 h rest where the text gives 0.005. Rescue analgesia: the count is patients given rescue analgesia, the median_iqr is bucinnazine mg, both within the first 48 h (text 0 [0-75] v 0 [0-100]; Table 4's decimals taken). Adverse events: Methods prespecify illusions, dissociation, diplopia, nystagmus, dizziness, dreams and urinary retention; the Results say 'Only 1 patient experienced an S-ketamine-related adverse event during the study' and the Discussion '1 case of diplopia that was self-limiting in the S-ketamine group'; the zeros come from those statements, not printed numerals (illusions coded as hallucination, dreams as nightmare). PONV 11 (28.2) vs 15 (39.5) not coded. The QoR-40 pain dimension is a recovery subscale and is not entered. Enrollment from the Results ('Between May 2021 and December 2021'). No registration date given. No blinding check.",
  "reason": "The coders agreed on every value; they differed only in that A wrote 'n': null in the four NRS entries (rest and coughing, days 1 and 2) and B left the key out. The Results text and the Figure 2 caption give no n for NRS, so n is null; kept A's explicit null, which matches the codebook's mean_sd fields."
 }
]